This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 200.00% and -0.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers (BMY) Gets European Commission Nod for Inrebic
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.
Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.
Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study
by Zacks Equity Research
Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
by Zacks Equity Research
Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.
Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for November 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Exelixis (EXEL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Exelixis' (EXEL) Cabometyx Combo Approved by FDA for RCC
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
Roche's (RHHBY) 9M20 Sales Affected by COVID-19 Outbreak
by Zacks Equity Research
Roche's (RHHBY) performance in the first nine months gets negatively impacted by coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Roche's Tecentriq + Avastin Gets Positive CHMP Opinion for HCC
by Zacks Equity Research
Roche's (RHHBY) combination of immuno-oncology drug, Tecentriq, and Avastin gets positive CHMP opinion for the treatment of advanced or unresectable HCC.
Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.
Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer
by Zacks Equity Research
Exelixis (EXEL) submits a supplemental new drug application to the FDA seeking approval of Cabometyx in combination with Opdivo for the treatment of advanced renal cell carcinoma.
Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter.